NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Mechanism of Action
cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade…
Clinical Trials (5)
The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group
Started Oct 2024
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Started Jun 2024
80 enrolled
Neuromuscular Blocks
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
Started Aug 2023
118 enrolled
Spine SurgeryReversal of Neuromuscular BlockadeUrinary Retention Postoperative
Sugammadex as Rescue Therapy
Started Jul 2023
46 enrolled
Neuromuscular Blockade
Comparison of Time to Extubation Using Sugammadex or Neostigmine
Started Apr 2021
58 enrolled
Neuromuscular BlockadeChronic Obstructive Pulmonary Disease
Loss of Exclusivity
LOE Date
Dec 12, 2027
21 months away
Patent Expiry
Jul 27, 2026
Exclusivity Expiry
Jun 12, 2028
Patent Records (2)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| RE44733 | Jan 27, 2026Expired | SubstanceProduct | U-1794 |
| RE44733*PED | Jul 27, 2026 | — |